Intravesical treatments of bladder cancer: review

Zancong Shen; Tong Shen; M Guillaume Wientjes; Michael A O'Donnell; Jessie L-S Au

doi:10.1007/s11095-008-9566-7

Back

Intravesical treatments of bladder cancer: review

Journal article

Open access

Peer reviewed

Intravesical treatments of bladder cancer: review

Zancong Shen, Tong Shen, M Guillaume Wientjes, Michael A O'Donnell and Jessie L-S Au

Pharmaceutical research, Vol.25(7), pp.1500-1510

07/2008

DOI: 10.1007/s11095-008-9566-7

PMCID: PMC2440939

PMID: 18369709

Files and links (1)

url

https://doi.org/10.1007/s11095-008-9566-7View

Published (Version of record) Open Access

Abstract

For bladder cancer, intravesical chemo/immunotherapy is widely used as adjuvant therapies after surgical transurethal resection, while systemic therapy is typically reserved for higher stage, muscle-invading, or metastatic diseases. The goal of intravesical therapy is to eradicate existing or residual tumors through direct cytoablation or immunostimulation. The unique properties of the urinary bladder render it a fertile ground for evaluating additional novel experimental approaches to regional therapy, including iontophoresis/electrophoresis, local hyperthermia, co-administration of permeation enhancers, bioadhesive carriers, magnetic-targeted particles and gene therapy. Furthermore, due to its unique anatomical properties, the drug concentration-time profiles in various layers of bladder tissues during and after intravesical therapy can be described by mathematical models comprised of drug disposition and transport kinetic parameters. The drug delivery data, in turn, can be combined with the effective drug exposure to infer treatment efficacy and thereby assists the selection of optimal regimens. To our knowledge, intravesical therapy of bladder cancer represents the first example where computational pharmacological approach was used to design, and successfully predicted the outcome of, a randomized phase III trial (using mitomycin C). This review summarizes the pharmacological principles and the current status of intravesical therapy, and the application of computation to optimize the drug delivery to target sites and the treatment efficacy.

Algorithms

Animals

Antineoplastic Agents - administration & dosage

Antineoplastic Agents - pharmacokinetics

Antineoplastic Agents - therapeutic use

Computer Simulation

Humans

Urinary Bladder Neoplasms - drug therapy

Details

Title: Subtitle: Intravesical treatments of bladder cancer: review
Creators: Zancong Shen - The Ohio State University
Tong Shen - The Ohio State University
M Guillaume Wientjes - The Ohio State University
Michael A O'Donnell
Jessie L-S Au - The Ohio State University
Resource Type: Journal article
Publication Details: Pharmaceutical research, Vol.25(7), pp.1500-1510
DOI: 10.1007/s11095-008-9566-7
PMID: 18369709
PMCID: PMC2440939
NLM abbreviation: Pharm Res
ISSN: 0724-8741
eISSN: 1573-904X
Grant note: R21CA111770 / NCI NIH HHS R21 CA111770 / NCI NIH HHS
Language: English
Date published: 07/2008
Academic Unit: Urology
Record Identifier: 9984320065802771

Metrics

24 Record Views

139 Times Cited - Web of Science

See more details